Thursday, 15 October 2026 | 15:10 - 16:30
Thematic session 4 – From promise to impact: How innovations successfully scale and reach patients
- Nuclear medicine
- Radioligand therapy (RLT)
- Radiotheranostics
- Oncology
- Precision medicine
- Health innovation
- Clinical innovation
- Patient impact
- Scaling innovation
- Public-private partnerships
- Academic-industry collaboration
- Market access
- Belgian excellence
This session will showcase Belgium’s excellence in nuclear medicine through concrete examples of innovation transforming clinical practice.
Key highlights include:
-
Three compelling success stories from leading Belgian actors
-
The development of breakthrough therapies and enabling technologies
-
The role of novel radioisotopes in advancing the field
-
How innovation moves from concept to clinical application
-
The tangible and measurable impact on patients
The session will also emphasize:
-
The strength and complementarity of the Belgian ecosystem
-
A broader view of national capabilities in nuclear medicine
It will conclude with:
-
A high-level roundtable gathering C-level leaders
-
A strategic discussion on how to sustain and strengthen
-
Belgium’s global leadership in a fast-evolving, competitive landscape
Why attend?
Understand how local excellence can drive global impact, and identify the key conditions needed to turn innovation into meaningful patient outcomes.
8 speakers
CEO
IRE
CEO
PanTera nv
CEO
ABSCINT
COO EMEA
Telix Pharmaceuticals
Director Nuclear Medicine Applications
SCK CEN
Head of the department of nuclear medicine
VUB
Senior Manager
PwC
CEO
TRASIS SA